- DCGEN
- DCGEN
- History
History
2026
- MFDS Market Approval - Newly Developed Medical Device
2025
- CAP Accreditation - No Deficiency
- Series B+ Funding (KRW 1.5B) - Medytox Venture Investment, IBKC-Medici Investment
- Achieved TI-1 (Highest) Tech Rating for Investment from SCI (Seoul Information Service inc.)
2024
- Selected for 'Materials, Parts, and Equipment Technology Development (R&D)' Project (MOTIE)
- Selected for 'Global Research Cooperation Support Project' (MOHW, MSIT / Boston Korea)
- Selected for '2024 Super Gap Startup 1000+ Project(DIPS)' (MSS / KISED)
- Certification of Inno-Biz
2023
- Minister’s Commendation from the Ministry of Trade, Industry and Energy (MOTIE)
- Minister’s Commendation from the Ministry of SMEs and Startups (MSS)
- Selected for 'Top 50 SME R&D Achievements' (TIPA)
2022
- Series B Funding (USD 7.3M (KRW 10B))
- 3 Patents registered, 5 patents applied
- Certification of Genetic Testing Institution
- Family Friendly Certified Company
2020
- Certification of GMP
- Certification of Frontier Venture Business
2019
- Investment from Premier Partners and Intervest (Series A)
- Know-how transfer of HOPE® from Seoul National University Hospital
- Technology transfer of OncoFREE® Algorithm from Seoul National University Hospital, Seoul National University Research & Business Foundation, Korea University Research & Business Foundation, Asan Medical Center, and Foundation for Industry Cooperation University of Ulsan
- Technology transfer of OncoFREE® Probe from Seoul National University Hospital and Seoul National University Research & Business Foundation
- Approval to manufacture medical devices for export of OncoFREE® from Ministry of Food and Drug Safety
- Certification of Corporate R&D Centers
- Certification of ISO 13485:2016
- Certification of CE
2018
- Certification of Venture Business
- Investment from Medytox Venture Investment (TIPS)
2017
- Corporation establishment
- Business initiation